Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan): The First Non-Immunosuppressive Treatment Proven to Effectively Slow Kidney Function Decline in IgA Nephropathy
FDA Approves Expansion of Indication for FILSPARI in IgA Nephropathy New Era of Treatment for IgA Nephropathy Patients The FDA has recently approved an expanded indication for FILSPARI, a promising oral medication for patients with IgA nephropathy (IgAN) who are at risk of disease progression. This updated label includes data from the PROTECT Study, showing…
